A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination therapy in Subjects with Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

  • Keating, Dominic (Primary Chief Investigator (PCI))
  • Wilson, John (Chief Investigator (CI))

Project: Research

Project Details

StatusFinished
Effective start/end date28/10/19 → 31/12/24

Keywords

  • Cystic Fibrosis
  • Clinical trial

Clinical Trial Phase

  • Phase III (a & b)